Kymera Q2 net loss $38.8M; cash $472M; Sanofi to start KT-474 Phase 2 in Q4 2023

Kymera Therapeutics, Inc.

2023-Q2 EPS reported -$1.37 revenue$25,979,000

Collaboration revenue $16.5M (up from $11.5M YoY); R&D expense $45.8M; net loss narrowed to $38.8M.
Cash & equivalents $472M as of June 30, 2023; cash runway into second half of 2025.
Partner Sanofi plans Phase 2 trials for KT-474 (IRAK4 degrader) in hidradenitis suppurativa and atopic dermatitis in Q4 2023.
Phase 1 data for KT-253 (MDM2), KT-333 (STAT3), KT-413 (IRAKIMiD) expected later in 2023.
Appointed Jeremy Chadwick as COO and Justine Koenigsberg as VP, Head of IR.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Kymera Therapeutics, Inc. reported the second quarter ended June 30, 2023 results: revenue $16.5 million.

Period: the second quarter ended June 30, 2023
Revenue: $16.5 million
Result: reported results

Exact text from the filing

. A replay of the webcast will be archived and available following the event. Second Quarter 2023 Financial Results Collaboration Revenues: Collaboration revenues were $16.5 million for the second quarter of 2023 compared to $11.5 million for the second quarter of 2022. Collaboration revenues include revenue from the Company’s Sanofi and Vertex

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

Kymera Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-037578

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.